We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Chi-Med Completes Patients Enrollment in Pivotal Phase III FRESCO Trial

News   May 14, 2016

 
Chi-Med Completes Patients Enrollment in Pivotal Phase III FRESCO Trial
 
 
Advertisement
 

RELATED ARTICLES

New Cancer Drug Targeting DNA Repair Shows Promise in Early-Stage Trial

News

A new precision drug which stops cancer from repairing its DNA has shown promise in an early-stage clinical trial – highlighting the potential of a new class of drugs known as ATR inhibitors.

READ MORE

Phase 3 Trial Assesses Dual-Antibody Injection's Ability To Prevent SARS-CoV-2 Infection

News

A Phase III, randomized, double-blinded, placebo-controlled trial will help to determine if the dual-antibody treatment, REGN-COV2, can prevent infection in individuals who share a home with someone who has been diagnosed with COVID-19.

READ MORE

University of New Hampshire Awarded $1.8 M To Explore Drug Interactions and Targeted Drug Development

News

The University of New Hampshire is set to receive $1.8 million from the National Institutes of Health. This will be used to further the university's research to better understand drug interactions at the cellular level and help develop new targeted drugs to treat disorders including diabetes and cancer.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE